Back to Search
Start Over
Chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis.
- Source :
-
NDT plus [NDT Plus] 2009 Aug; Vol. 2 (4), pp. 309-11. Date of Electronic Publication: 2009 Apr 23. - Publication Year :
- 2009
-
Abstract
- A 65-year-old female with biopsy-confirmed nephrogenic systemic fibrosis (NSF) received a kidney transplantation. Despite good kidney function, her symptoms continued to progress. Deferoxamine was administered intramuscularly at 500 mg/day and later 1000 mg/day after 1 week with no adverse effects. Urine excretion of gadolinium increased from 6.0 μg/day to 11.6 μg/day and subsequently to 13.0 μg/day with 500 mg/day and 1000 mg/day of deferoxamine, respectively. Serum levels, however, remain unchanged from 1.7 ng/ml to 1.4 ng/ml. Although chelation therapy may have a role in the treatment of NSF, deferoxamine is too weak and a stronger chelator is needed.
Details
- Language :
- English
- ISSN :
- 1753-0784
- Volume :
- 2
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- NDT plus
- Publication Type :
- Report
- Accession number :
- 25984024
- Full Text :
- https://doi.org/10.1093/ndtplus/sfp042